Inhaled nitric oxide and oral nifedipine in a preterm infant with bronchopulmonary dysplasia and pulmonary hypertension
β Scribed by Enrico Rosati; Gianfranco Butera; Eduardo Bossone; Claudio De Felice; Giuseppe Latini
- Publisher
- Springer
- Year
- 2006
- Tongue
- English
- Weight
- 59 KB
- Volume
- 166
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Patients with moderate and severe pulmonary hypertension have a very high mortality rate when undergoing orthotopic liver transplantation. Because nitric oxide has been successful in reducing pulmonary artery pressures in certain patients with pulmonary hypertension, the efficacy of NO inhalation (4
Inhaled nitric oxide (NO) is currently used as an adjuvant therapy for a variety of pulmonary hypertensive disorders. In both animal and human studies, inhaled NO induces selective, dose-dependent pulmonary vasodilation. However, its potential interactions with other simultaneously used pulmonary va
Does inhaled nitric oxide (iNO) decrease the rates of death, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), or neurodevelopmental disability in preterm newborn infants with early signs of respiratory failure? ## Background Respiratory failure in the preterm newborn may be com